Xenon Pharmaceuticals (XENE) Accumulated Depreciation & Amortization: 2013-2024
- Xenon Pharmaceuticals' Accumulated Depreciation & Amortization rose 349.63% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.2 million, marking a year-over-year decrease of 34.43%. This contributed to the annual value of $1.4 million for FY2024, which is 349.63% up from last year.
- According to the latest figures from Q4 2024, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization is $1.4 million, which was up 349.63% from -$542,000 recorded in Q4 2023.
- Xenon Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $5.1 million during Q4 2020, with a 5-year trough of -$542,000 in Q4 2023.
- Over the past 3 years, Xenon Pharmaceuticals' median Accumulated Depreciation & Amortization value was $1.4 million (recorded in 2024), while the average stood at $1.1 million.
- Per our database at Business Quant, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization crashed by 122.39% in 2023 and then surged by 349.63% in 2024.
- Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Accumulated Depreciation & Amortization stood at $5.1 million in 2020, then fell by 22.83% to $4.0 million in 2021, then slumped by 38.83% to $2.4 million in 2022, then crashed by 122.39% to -$542,000 in 2023, then skyrocketed by 349.63% to $1.4 million in 2024.
- Its Accumulated Depreciation & Amortization was $1.4 million in Q4 2024, compared to -$542,000 in Q4 2023 and $2.4 million in Q4 2022.
